Bavarian Nordic today announced that it and its partner Janssen Pharmaceuticals, part of Johnson & Johnson, have submitted an application to the European Medicines Agency (EMA) for approval of their investigational two-dose Ebola vaccine regimen (Ad26.ZEBOV, MVA-BN Filo).

The news comes as one new Ebola case was reported today in the Democratic Republic of the Congo (DRC) outbreak, part of a fluctuating pattern that the World Health Organization (WHO) noted today in its weekly snapshot of the event.

J&J vaccine before European regulators

iStock, MarianVejcik

Read more at CIDRAP…

Photo credit:  (CC BY 2.0), flickr, Aalok Kanani